OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Risk of hospitalization and sequelae in patients with COVID‐19 treated with 3‐day early remdesivir vs. controls in the vaccine and Omicron era: A real‐life cohort study
Maria Mazzitelli, Mattia Trunfio, Lolita Sasset, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 20
Maria Mazzitelli, Mattia Trunfio, Lolita Sasset, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 20
Showing 20 citing articles:
Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave
Yeonju La, Won Sup Oh, Changhyup Kim, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Yeonju La, Won Sup Oh, Changhyup Kim, et al.
BMC Infectious Diseases (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Remdesivir: A Review in COVID-19
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 27
Hannah A. Blair
Drugs (2023) Vol. 83, Iss. 13, pp. 1215-1237
Open Access | Times Cited: 27
The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 5
Gangqiang Sun, Ke Lin, Jingwen Ai, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 12, pp. 1505-1513
Closed Access | Times Cited: 5
Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study
Antonio Russo, Mariantonietta Pisaturo, Chiara Cacace, et al.
Pathogens (2025) Vol. 14, Iss. 3, pp. 216-216
Open Access
Antonio Russo, Mariantonietta Pisaturo, Chiara Cacace, et al.
Pathogens (2025) Vol. 14, Iss. 3, pp. 216-216
Open Access
Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study
Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1515-1515
Open Access | Times Cited: 10
Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1515-1515
Open Access | Times Cited: 10
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 3
Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
Anhua Wei, Lu Zeng, Lu Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Anhua Wei, Lu Zeng, Lu Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis
Nicola Veronese, Francesco Di Gennaro, Luisa Frallonardo, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Nicola Veronese, Francesco Di Gennaro, Luisa Frallonardo, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study
Vasiliki Georgakopoulou, Aikaterini Gkoufa, Sotiria Makrodimitri, et al.
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 4
Open Access | Times Cited: 7
Vasiliki Georgakopoulou, Aikaterini Gkoufa, Sotiria Makrodimitri, et al.
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 4
Open Access | Times Cited: 7
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
Nan Shang, Xianlin Li, Zhiyu Guo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Nan Shang, Xianlin Li, Zhiyu Guo, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Retrospective Analysis of the Outcome of Hospitalized COVID-19 Patients with Coexisting Metabolic Syndrome and HIV Using Multinomial Logistic Regression
Peter M. Mphekgwana, Musa E. Sono-Setati, Tania V. Mokgophi, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 10, pp. 5799-5799
Open Access | Times Cited: 3
Peter M. Mphekgwana, Musa E. Sono-Setati, Tania V. Mokgophi, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 10, pp. 5799-5799
Open Access | Times Cited: 3
Evolution of in-hospital patient characteristics and predictors of death in the COVID-19 pandemic across four waves: are they moving targets with implications for patient care?
Enrico Maria Trecarichi, Vincenzo Olivadese, Chiara Davoli, et al.
Frontiers in Public Health (2024) Vol. 11
Open Access
Enrico Maria Trecarichi, Vincenzo Olivadese, Chiara Davoli, et al.
Frontiers in Public Health (2024) Vol. 11
Open Access
Update on efficacy of the approved remdesivir regimen for treatment of COVID-19: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials
George N. Okoli, Viraj K. Reddy, Olt Lam, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 8, pp. 1277-1287
Closed Access
George N. Okoli, Viraj K. Reddy, Olt Lam, et al.
Current Medical Research and Opinion (2024) Vol. 40, Iss. 8, pp. 1277-1287
Closed Access
Utilizing Feline Lentiviral Infection to Establish a Translational Model for COVID-19 in People with Human Immunodeficiency Virus Infection
Shoroq Shatnawi, Sachithra Gunasekara, Laura Bashor, et al.
Microorganisms (2024) Vol. 12, Iss. 7, pp. 1289-1289
Open Access
Shoroq Shatnawi, Sachithra Gunasekara, Laura Bashor, et al.
Microorganisms (2024) Vol. 12, Iss. 7, pp. 1289-1289
Open Access
The effect of early versus late remdesivir treatment in hospitalized mild to moderate COVID-19 patients in the Omicron era: A retrospective study
Byung-Han Ryu, Ju Young Lee, Sun Hee Lee
Medicine (2024) Vol. 103, Iss. 29, pp. e39035-e39035
Open Access
Byung-Han Ryu, Ju Young Lee, Sun Hee Lee
Medicine (2024) Vol. 103, Iss. 29, pp. e39035-e39035
Open Access
Clinical outcomes of early remdesivir administration in hospitalized patients at high risk for severe COVID-19 during the Omicron wave
Yeonju La, Won Sup Oh, Changhyup Kim, et al.
Research Square (Research Square) (2024)
Open Access
Yeonju La, Won Sup Oh, Changhyup Kim, et al.
Research Square (Research Square) (2024)
Open Access
Impact of oral early antiviral therapies for mild–moderate COVID-19 in the outpatient’s setting during Omicron era: a pharmacoeconomic analysis
Vincenzo Scaglione, Samuele Gardin, Lolita Sasset, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access
Vincenzo Scaglione, Samuele Gardin, Lolita Sasset, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge
Claudia Bartalucci, Alessandro Limongelli, Laura Ambra Nicolini, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 4, pp. 283-290
Closed Access | Times Cited: 1
Claudia Bartalucci, Alessandro Limongelli, Laura Ambra Nicolini, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 4, pp. 283-290
Closed Access | Times Cited: 1
Real Life Experience on the Use of Remdesivir in Patients Admitted to Covid-19 in Two Referral Italian Hospital: a Propensity Score Matched Analysis
Nicola Veronese, Francesco Di Gennaro, Luisa Frallonardo, et al.
Research Square (Research Square) (2023)
Open Access
Nicola Veronese, Francesco Di Gennaro, Luisa Frallonardo, et al.
Research Square (Research Square) (2023)
Open Access
Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases
Atsushi Suzuki, Kensuke Fukumitsu, Jun Fukihara, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 2, pp. 127-132
Closed Access
Atsushi Suzuki, Kensuke Fukumitsu, Jun Fukihara, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 2, pp. 127-132
Closed Access
